Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
Data heterogeneity is a regulatory reviewer’s nightmare. Some sponsors talk about patient “gender” whereas others list the patient’s “sex.” What about date formats? Do you use the American-style month-day-year format or the European-style day-month-year? Inconsistent data presentation makes both collaborating on drug development projects and reviewing regulatory submissions more difficult. To address this challenge, the […]
Read MorePRINCETON, NJ – Apr. 19, 2017 – Certara today announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of non-clinical and clinical data.
Read MoreThrough our collaborations with regulatory agencies, and partnerships with major global nonprofits, we, at Certara, continuously strive to provide up-to-date solutions to help streamline the drug development process for our clients. Beginning at the end of 2016, in a continuing effort towards international harmonization across regulatory agencies, the US Food and Drug Administration (FDA), the […]
Read More
A recent report by Deloitte identified the #1 trend in the life sciences market as an increased focus on patient safety and enforcement. While it seems obvious to consider safety issues in approved drugs, regulatory agencies such as the FDA and EMA (European Medicines Agency) are extending their scrutiny to the entire drug development process, […]
Read More